Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: An open preliminary trial in Japan

Journal of Clinical Neuroscience

Volumn 16, Issue 6, 2009, Pages 790-792

  Ohno, Hideki ^a,b   Nakajima, Masashi ^a   Fujioka, Shinsuke ^a   Iwamoto, Kohnosuke ^a   Kawamura, Mitsuru ^b  

^a TOKYO ROSAI HOSPITAL   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cabergoline; Dopamine agonist; Parkinson's disease; Pramipexole

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; TRIHEXYPHENIDYL;

AGED; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DOPAMINERGIC ACTIVITY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; IMMOBILIZATION; JAPAN; MALE; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

BENZOTHIAZOLES; BROMOCRIPTINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERGOLINES; HUMANS; JAPAN; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PERGOLIDE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349123776     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.09.001     Document Type: Article

References (15)

1. Schade R., Andersohn F., Suissa S., et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (2007) 29-38
2. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
3. Goetz C.G., Tanner C.M., and Glantz R.H. Chronic agonist therapy for Parkinson's disease: a five-year study of bromocriptine and pergolide. Neurology 35 (1985) 749-751
4. Goetz C.G., Shannon K.M., and Tanner C.M. Agonist substitution in advanced Parkinson's disease. Neurology 39 (1989) 1121-1122
5. Goetz C.G., Blasucci L., and Stebbins G.T. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?. Neurology 52 (1999) 1227-1229
6. Linazasoro G., and Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 251 (2004) 335-339
7. Baas H.K., and Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 46 suppl 1 (2001) 18-23
8. Grosset K., Needleman F., Macphee G., et al. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 19 (2004) 1370-1374
9. Stewart D., Morgan E., Burn D., et al. Dopamine agonist switching in Parkinson's disease. Hosp Med 65 (2004) 215-219
10. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 28 (2006) 1-12
11. Hughes A.J., Daniel S.E., Kilford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
12. Rinne U.K., Bracco F., Chouza C., et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 (1998) 23-30
13. Parkinson Study Group. Pramipexole vs levodopa as initial treatment of Parkinson's disease: a randomized controlled trial. JAMA 2000;284:1931-8.
14. Wright C.E., Sisson T.L., Ichhpurani A.K., et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 37 (1997) 520-525
15. Hubble J.P. Pre-clinical studies of pramipexole: clinical relevance. Eur J Neurol 7 Suppl 1 (2000) 15-20